| Literature DB >> 26383016 |
Daniel J Urban1, Hu Zhu1, Catherine A Marcinkiewcz2, Michael Michaelides3, Hidehiro Oshibuchi4, Darren Rhea4, Dipendra K Aryal5, Martilias S Farrell1, Emily Lowery-Gionta2, Reid H J Olsen1, William C Wetsel5, Thomas L Kash2, Yasmin L Hurd3, Laurence H Tecott4, Bryan L Roth1.
Abstract
Elucidating how the brain's serotonergic network mediates diverse behavioral actions over both relatively short (minutes-hours) and long period of time (days-weeks) remains a major challenge for neuroscience. Our relative ignorance is largely due to the lack of technologies with robustness, reversibility, and spatio-temporal control. Recently, we have demonstrated that our chemogenetic approach (eg, Designer Receptors Exclusively Activated by Designer Drugs (DREADDs)) provides a reliable and robust tool for controlling genetically defined neural populations. Here we show how short- and long-term activation of dorsal raphe nucleus (DRN) serotonergic neurons induces robust behavioral responses. We found that both short- and long-term activation of DRN serotonergic neurons induce antidepressant-like behavioral responses. However, only short-term activation induces anxiogenic-like behaviors. In parallel, these behavioral phenotypes were associated with a metabolic map of whole brain network activity via a recently developed non-invasive imaging technology DREAMM (DREADD Associated Metabolic Mapping). Our findings reveal a previously unappreciated brain network elicited by selective activation of DRN serotonin neurons and illuminate potential therapeutic and adverse effects of drugs targeting DRN neurons.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26383016 PMCID: PMC4793125 DOI: 10.1038/npp.2015.293
Source DB: PubMed Journal: Neuropsychopharmacology ISSN: 0893-133X Impact factor: 7.853